Earns revenue mainly from partner-funded development of its allogeneic cell replacement therapies — the Roche-Genentech OpRegen license (recognised upfront fees, a first development milestone, funded services) and the WDI-funded ReSonance research collaboration — plus small royalties from sublicensees' product sales under acquired patent families.
